TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immediate Versus Delayed IUD Insertion Following Suction Aspiration Between 5 and 12 Weeks Gestation: a Randomized Trial
Brief Summary: The purpose of this multi-center clinical trial is to evaluate the safety and effectiveness of inserting an intrauterine device (IUD) immediately after a suction aspiration procedure compared to inserting the IUD 2-6 weeks after the procedure. This study will also evaluate how satisfied women are with the timing of their IUD placement. Subjects will be able to choose between the Paraguard IUD or the Mirena IUD.

The researchers hypothesize that:

1. the expulsion rates measured at 1, 3 and 6 months will be clinically equivalent with immediate insertion compared with delayed insertion,
2. satisfaction and tolerance of side effects will be higher with immediate IUD insertion compared with delayed insertion, and
3. overall IUD use/continuation rates measured at 1, 3 and 6 months will be higher with immediate IUD insertion compared with delayed insertion.


Options:
A: Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo Gel | Arm Label: Nitroprusside Gel; Type: EXPERIMENTAL; Interventions: Procedure: Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Nitroprusside Gel; Assigned to Arm(s): Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Placebo Gel; Assigned to Arm(s): Placebo gel
B: Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Oxygen (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Oxygen | Arm Label: Nitrous Oxide (NO); Type: EXPERIMENTAL; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Nitrous oxide | Intervention Type: PROCEDURE; Name: IUD insertion; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Povidone-Iodine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: OTHER; Name: Oxygen; Assigned to Arm(s): Oxygen (Placebo) | Intervention Type: OTHER; Name: Nitrous oxide; Assigned to Arm(s): Nitrous Oxide (NO)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Immediate IUD insertion | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Immediate IUD insertion; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)
Brief Summary: The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Avastin (Bevacizumab) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Avastin (Bevacizumab) | Intervention Type: DRUG; Name: Avastin (Bevacizumab); Assigned to Arm(s): 1, 2
B: Arm Label: 1-ranibizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: 2-ranibizumab with laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: 3-laser monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 1-ranibizumab monotherapy, 2-ranibizumab with laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): 2-ranibizumab with laser, 3-laser monotherapy
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 2, 3 | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.
Brief Summary: This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe complications following influenza infection.


Options:
A: Arm Label: Influenza vaccine; Type: EXPERIMENTAL; Interventions: Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Phosphate buffered saline | Intervention Type: BIOLOGICAL; Name: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived); Assigned to Arm(s): Influenza vaccine | Intervention Type: OTHER; Name: Phosphate buffered saline; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: CSL Limited Influenza Vaccine | Arm Label: 2; Type: OTHER; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL Limited Influenza Vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Total vaccinated cohort; Type: N/A; Interventions: Other: Safety follow up | Intervention Type: OTHER; Name: Safety follow up; Assigned to Arm(s): Total vaccinated cohort
D: Arm Label: CSL425 (7.5 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (15 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (30 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (7.5 mcg) | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (15 mcg), CSL425 (30 mcg) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study
Brief Summary: German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting. They argue that clinical experience with sub-acute Aggrenox treatment is limited and poorly documented when compared with sub-acute acetylsalicylic acid (ASA) treatment. However, long term treatment (started after 3-6 months after stroke/TIA) with Aggrenox was safe and superior to ASA treatment in preventing recurrent strokes. There is no evidence for ASA to prevent from neurological progression after stroke during the first 3 months. Results from a cohort study suggest that starting Aggrenox within 72 hours after stroke predicts clinical improvement in the National Institute of Health Stroke Scale (NIHSS) at discharge from the hospital. Dipyridamole suppresses acute inflammatory responses to stroke.

This study is designed to investigate the tolerability and efficacy of a secondary stroke prevention treatment with Aggrenox when initiated within 24 hours of stroke onset on a stroke unit compared to later initiation after a 7 day ASA treatment and outside off a stroke unit setting.


Options:
A: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A
C: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
D: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study
Brief Summary: German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting. They argue that clinical experience with sub-acute Aggrenox treatment is limited and poorly documented when compared with sub-acute acetylsalicylic acid (ASA) treatment. However, long term treatment (started after 3-6 months after stroke/TIA) with Aggrenox was safe and superior to ASA treatment in preventing recurrent strokes. There is no evidence for ASA to prevent from neurological progression after stroke during the first 3 months. Results from a cohort study suggest that starting Aggrenox within 72 hours after stroke predicts clinical improvement in the National Institute of Health Stroke Scale (NIHSS) at discharge from the hospital. Dipyridamole suppresses acute inflammatory responses to stroke.

This study is designed to investigate the tolerability and efficacy of a secondary stroke prevention treatment with Aggrenox when initiated within 24 hours of stroke onset on a stroke unit compared to later initiation after a 7 day ASA treatment and outside off a stroke unit setting.


Options:
A: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
B: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best medical therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: STARFlex septal closure system | Intervention Type: DEVICE; Name: STARFlex septal closure system; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Best medical therapy; Assigned to Arm(s): 1
D: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease
Brief Summary: Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events


Options:
A: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
C: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan, Bisoprolol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan, Bisoprolol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monitoring Asthma Treatment Using Exhaled Nitric Oxide
Brief Summary: Asthma is a chronic inflammatory condition in which the airways develop increased responsiveness to various stimuli such as exposure to an allergen, cold air or exercise. It is characterized by airway hyper-responsiveness, inflammation, increased mucus production, and airway obstruction. Since inflammation is an important feature of asthma, the use of non-invasive tests to measure lung inflammation to monitor asthma are of interest.The purpose of the study is to relate costs associated with healthcare utilization and loss of work and school time to the primary health outcome of cumulative number of symptom-free days. This will enable the researchers to determine whether the costs of monitoring exhaled NO to regular management strategy in recently diagnosed asthma will be offset by reductions in other costs of asthma-related care, and, if not, whether the additional costs are likely to be acceptable in terms of the improvement in health outcomes as measured by the additional number of symptom-free days.


Options:
A: Arm Label: High dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Arm Label: Low dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Low dose ICS | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): High dose ICS
B: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
C: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
D: Arm Label: FeNO group; Type: N/A; Interventions: Device: measurement of exhaled NO is used to guide treatment | Arm Label: Symptom group; Type: N/A; Interventions: N/A | Intervention Type: DEVICE; Name: measurement of exhaled NO is used to guide treatment; Assigned to Arm(s): FeNO group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monitoring Asthma Treatment Using Exhaled Nitric Oxide
Brief Summary: Asthma is a chronic inflammatory condition in which the airways develop increased responsiveness to various stimuli such as exposure to an allergen, cold air or exercise. It is characterized by airway hyper-responsiveness, inflammation, increased mucus production, and airway obstruction. Since inflammation is an important feature of asthma, the use of non-invasive tests to measure lung inflammation to monitor asthma are of interest.The purpose of the study is to relate costs associated with healthcare utilization and loss of work and school time to the primary health outcome of cumulative number of symptom-free days. This will enable the researchers to determine whether the costs of monitoring exhaled NO to regular management strategy in recently diagnosed asthma will be offset by reductions in other costs of asthma-related care, and, if not, whether the additional costs are likely to be acceptable in terms of the improvement in health outcomes as measured by the additional number of symptom-free days.


Options:
A: Arm Label: High dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Arm Label: Low dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Low dose ICS | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): High dose ICS
B: Arm Label: FeNO group; Type: N/A; Interventions: Device: measurement of exhaled NO is used to guide treatment | Arm Label: Symptom group; Type: N/A; Interventions: N/A | Intervention Type: DEVICE; Name: measurement of exhaled NO is used to guide treatment; Assigned to Arm(s): FeNO group
C: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
D: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy & Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent & Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
Brief Summary: Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil® (Formoterol) in adolescent and adult patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort Turbuhaler | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort Turbuhaler, Drug: Terbutaline Turbuhaler | Intervention Type: DRUG; Name: Symbicort Turbuhaler; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Terbutaline Turbuhaler; Assigned to Arm(s): 2
B: Arm Label: Flutiform; Type: EXPERIMENTAL; Interventions: Drug: Flutiform | Arm Label: Flixotide plus Foradil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide plus Foradil | Intervention Type: DRUG; Name: Flutiform; Assigned to Arm(s): Flutiform | Intervention Type: DRUG; Name: Flixotide plus Foradil; Assigned to Arm(s): Flixotide plus Foradil
C: Arm Label: Symbicort "as needed"+placebo Pulmicort bid; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid | Arm Label: terbutaline "as needed"+placebo Pulmicort bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline 'as needed' + placebo budesonide bid | Arm Label: Pulmicort bid + terbutaline "as needed"; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide bid + terbutaline 'as needed' | Intervention Type: DRUG; Name: budesonide/formoterol 'as needed' + budesonide placebo bid; Assigned to Arm(s): Symbicort "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: terbutaline 'as needed' + placebo budesonide bid; Assigned to Arm(s): terbutaline "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: budesonide bid + terbutaline 'as needed'; Assigned to Arm(s): Pulmicort bid + terbutaline "as needed"
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide, Drug: terbutaline | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide/formoterol | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: terbutaline; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): C

Answer: B